Hemab Therapeutics【COAG】銘柄情報

Hemab Therapeutics Holdings Inc (COAG) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

32.37

( 16.77% )

買値

31.74

売値

33.01

出来高

329,192

27.56 日の範囲 33.18

23.0001 52 週間の範囲 32.40

時価総額

1.512B

前日終値

27.72

始値

27.56

時刻

33.01

最終取引時間

06:15:42

財務取引量

US$ 10,414,817

VWAP

31.6375

平均取引量 (3 か月)

US$ 367,186

発行済株式数

46,705,410

配当利回り

PER

-0.38

1 株当たり利益 (EPS)

-75.36

歳入

純利益

-71.29M

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibod... Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts. 詳細を表示

セクター

業界

ウェブサイト

www.hemab.com

本社

Cambridge, United States

設立

2026

Hemab Therapeutics Holdings Inc is listed in the sector of the ナスダック市場 with ticker COAG. The last closing price for Hemab Therapeutics was US$27.72. Over the last year, Hemab Therapeutics shares have traded in a share price range of US$ 23.0001 to US$ 32.40.

Hemab Therapeutics currently has 46,705,410 shares in issue. The market capitalisation of Hemab Therapeutics is US$1.51 billion. Hemab Therapeutics has a price to earnings ratio (PE ratio) of -0.38.

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress

New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD...

Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Hemab Therapeutics Reports First Quarter 2026 Financial Results

Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership

Form 8-K - Current report

Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 04, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage...

Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	3.12	10.6666666667	29.25	32.4	27.4725	241289	29.86228139	CS
4	4.67	16.8592057762	27.7	32.4	23.8065	283374	27.69444999	CS
12	1.5	4.85908649174	30.87	32.4	23.0001	259402	27.01616818	CS
26	1.5	4.85908649174	30.87	32.4	23.0001	259402	27.01616818	CS
52	1.5	4.85908649174	30.87	32.4	23.0001	259402	27.01616818	CS
156	1.5	4.85908649174	30.87	32.4	23.0001	259402	27.01616818	CS
260	1.5	4.85908649174	30.87	32.4	23.0001	259402	27.01616818	CS